ClinicalTrials.gg
CompletedNCT04438005DLBCLUpdated May 13, 2024

A Study of ICP-022 in Patients With R/R DLBCL

A Phase 2 interventional study of ICP-022 in Diffuse Large B Cell Lymphoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
11th of 11
3 · median 39
Started
2020
the only one that year
Phase 2
8 of 11
6 open now
Registered
1st of 11
by date
Lead sponsor
2 of 11
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 8 in phase 2, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There will be no control group in this study. Each subject will receive treatment orally every day in 28-day cycles. Each cycle starts immediately after the previously completed cycle without a break between cycles.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • Relapsed/Refractory
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. Men and women between 18 and 75 years old,
  2. confirmed diffuse large B-cell lymphoma(DLBCL)with MyD88 L265P and CD79B positive, at least one measurable tumor of greater than 1.5 centimeter in long axis by contrast-enhanced CT/MRI,
  3. performance status of 0-2,
  4. Voluntary written prior to trail screening.

Key Exclusion criteria:

  1. History of other active , unless cured without evidence of relapse or within 5 years of study entry
  2. History of Richter's syndrome
  3. Current or history of lymphoma involved central nervous system
  4. Prior (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody based therapies or anti-cancer TCM within 4 weeks of the start of study drug.
  5. The investigator considers other conditions unsuitable for this study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ICP-022

    Drug: ICP-022

Interventions

  • ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.

06

What researchers measure

Primary outcomes

  1. Overall response rate(ORR)

    The efficacy measured by overall response rate (ORR) according to the 2014 International Working Group NHL

    Time frame: Up to 3 years

Secondary outcomes

  1. Occurrence of adverse events and serious adverse events

    The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 5.0 grading criteria

    Time frame: Up to 3 years

  2. Progression free survival(PFS)

    The efficacy measured by progression free survival(PFS)

    Time frame: Up to 3 years

  3. Duration of response(DOR)

    Time frame: Up to 3 years

07

Study locations

7 sites
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Affiliated Tumor Hospital of Harbin Medical University
    Haerbin, Heilongjiang, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • The Fourth Hospital of Hebei Medical University
    Hebei, Shijiazhuang, China
  • Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
    Tianjin, Tianjin, China
  • The First Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Nov 2021, 17 months.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 17 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 18, 2020
StartActual
May 7, 2020
Primary completionActual
Nov 5, 2021
CompletionActual
Dec 13, 2021
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04438005
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
May 7, 2020
Primary completion
Nov 5, 2021
Completion
Dec 13, 2021
Last update
May 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion